Judith Wilson
Dillon, MTNPI 1164453932
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Amgen at 25.5% of the total. Reporting peaked in 2022 at $362 and has fallen 95.2% since, to $18 in 2025.
Across 61 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$291
- AbbVie$191
- Novo Nordisk$123
- Teva Pharmaceuticals USA, Inc.$71
- AstraZeneca$65
- Lilly USA, LLC$64
- plus $337 from 14 others
What the payments were for
- Food & beverage$1,03991%
- Education$1029%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $291 |
| AbbVie | 9 | $191 |
| Novo Nordisk | 8 | $123 |
| Teva Pharmaceuticals USA, Inc. | 3 | $71 |
| AstraZeneca | 5 | $65 |
| Lilly USA, LLC | 3 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Johnson & Johnson | 3 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Radius Health, Inc. | 2 | $29 |
| GSK | 2 | $27 |
| Alkermes, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Pfizer | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 20 | $38,596 |
| MounjaroTirzepatide | 15 | $16,795 |
| OzempicSemaglutide | 11 | $14,004 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $11,724 |
| Liothyronine Sodium | 65 | $2,781 |
| SynthroidLevothyroxine Sodium | 14 | $1,170 |
| Atorvastatin Calcium | 45 | $731 |
| Ezetimibe | 27 | $652 |
| Levothyroxine Sodium | 67 | $556 |
| ValacyclovirValacyclovir Hcl | 16 | $538 |
| Losartan Potassium | 45 | $375 |
| Ondansetron OdtOndansetron | 36 | $359 |
| Omeprazole | 27 | $299 |
| Montelukast Sodium | 30 | $264 |
| Amitriptyline Hcl | 13 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $64 | $16,79515 claims |
| Novo NordiskOzempic | $123 | $14,00411 claims |
| AbbVieSynthroid | $191 | $1,17014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Montanaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.